Uveites / AIDS
Instituição onde foi realizado o trabalho
- Principal: Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo
- RENATO RODRIGUES PEREIMA (Interesse Comercial: NÃO)
- Fernanda Maria Silveira Souto (Interesse Comercial: NÃO)
- Bárbara Vilela Giampietro (Interesse Comercial: NÃO)
- Júlia Thiemi Takiuti (Interesse Comercial: NÃO)
- Lúcia Maria Arruda Campos (Interesse Comercial: NÃO)
- Carlos Eduardo Hirata (Interesse Comercial: NÃO)
- Joyce Hisae Yamamoto (Interesse Comercial: NÃO)
CLINICAL FEATURES OF PEDIATRIC UVEITIS AT A TERTIARY REFERRAL CENTER IN SAO PAULO, SP, BRAZIL
To analyze clinical features, systemic associations, treatment and visual outcomes of uveitis in children from referral center in São Paulo, SP, Brazil.
Clinical records of patients under 16 years old who were followed up at Uveitis Service, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo between April and September 2017 were reviewed retrospectively. Patients with incomplete medical records, previous ocular trauma or less than 6 months of follow-up were excluded. Study approved by Institutional Ethics Committee (CapPesq 2.289.047) and was conducted in accordance with principles of Declaration of Helsinki.
Thirty-nine children (25F/14M) were included. There was predominance of bilateral (89.7%), asymptomatic (56.4%) and recurrent/chronic cases (84.6%). Median age at study inclusion was 10.7±3.4 years old (range 3–16 years). Visual acuity (VA) ≥ 20/60 in better eye was observed in 74% of patients at first visit and in 90% at final visit. Patients were referred early to tertiary center (55% within 6 months of uveitis diagnosis). Anterior uveitis was most common involvement (46%) followed by intermediate uveitis (26%). Juvenile idiopathic arthritis (JIA)-associated uveitis (41%) and immune-mediated intermediate uveitis (25.6%) were principal non-infectious conditions; ocular toxoplasmosis (7.7%) and toxocariasis (5.1%) were most common infectious conditions. Ocular complications were observed at first visit in 46% of patients and in 90% during final evaluation. Oral prednisone was used in all non-infectious conditions (32 children, 82%); IMT and/or biologic agents were used in all patients with JIA-associated uveitis and in 50% of patients with immune-mediated intermediate uveitis.
Pediatric patients with uveitis are referred early to this center and, although severe, adequate management with systemic IMT may preserve VA.